SABBY MANAGEMENT, LLC
Long book
$5.7M
Q1 2026
Positions
22
Top-10 weight
81%
concentration
Last quarter
+1.9%
SPY +14.8%
Turnover
76%
of book per quarter
Strategy in plain words
auto-generated from filingsSABBY MANAGEMENT, LLC is an institutional manager, running a $5.7M US long book across 22 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: SS SPDR S&P 500 ETF TRUST-US, ALPHA COMPUTE CORP, BRIACELL THERAPEUTICS CORP, SENESTECH INC, BIG TREE CLOUD HOLDINGS LT-A.
Over the last 9 quarters its long book ran on average 9.5pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. Signal value of individual moves is limited — treat changes as weak evidence.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-30.3%
Q2 2024
-6.0%
Q3 2024
-1.3%
Q4 2024
+20.0%
Q1 2025
+26.7%
Q2 2025
+24.2%
Q3 2025
-56.3%
Q4 2025
-24.5%
Q1 2026
+1.9%
Sector allocation
Healthcare 37%
Other 23%
Financials 22%
Services media 7%
Energy 5%
Materials 5%
Long book by quarter
What does SABBY MANAGEMENT, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ALP ALPHA COMPUTE CORP | Financials | 2.1M | $655K | 11.5% | New |
| SNES SENESTECH INC | Other | 218.5K | $358K | 6.3% | +3.8% |
| DSY BIG TREE CLOUD HOLDINGS LT-A | Other | 137.6K | $337K | 5.9% | New |
| BCTX BRIACELL THERAPEUTICS CORP | Healthcare | 73.9K | $310K | 5.4% | New |
| CPOP POP CULTURE GROUP CO LTD-A | Services media | 664.4K | $201K | 3.5% | -30.5% |
| MBRX MOLECULIN BIOTECH INC | Healthcare | 75.0K | $172K | 3.0% | New |
| RKDA ARCADIA BIOSCIENCES INC | Energy | 114.6K | $158K | 2.8% | New |
| TRX TRX GOLD CORP | Materials | 100.0K | $150K | 2.6% | New |
| INM INMED PHARMACEUTICALS INC | Healthcare | 220.3K | $142K | 2.5% | +9.2% |
| SXTC CHINA SXT PHARMACEUTICALS-A | Healthcare | 78.2K | $131K | 2.3% | New |
| REVB REVELATION BIOSCIENCES INC | Healthcare | 99.4K | $119K | 2.1% | New |
| CLDI CALIDI BIOTHERAPEUTICS INC | Healthcare | 434.9K | $104K | 1.8% | New |
| BJDX BLUEJAY DIAGNOSTICS INC | Healthcare | 28.7K | $53K | 0.9% | New |
| LYRA LYRA THERAPEUTICS INC | Healthcare | 104.1K | $51K | 0.9% | -40.6% |
| TPST TEMPEST THERAPEUTICS INC | Healthcare | 17.9K | $29K | 0.5% | -90.0% |
| BNBX BNB PLUS CORP | Services media | 13.5K | $9K | 0.2% | -74.9% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 28 | $45.1M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 33 | $69.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 39 | $86.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 43 | $55.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 46 | $34.0M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 27 | $76.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 42 | $186.4M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 39 | $148.71B | $K fixed canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 55 | $173.3M | canonical | SEC ↗ |
Similar funds
MASSACHUSETTS FINANCIAL SERVICES CO /MA/JENNISON ASSOCIATES LLCNational Pension ServiceFIL LtdClearbridge Investments, LLCDZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am MainNORDEA INVESTMENT MANAGEMENT ABBoston PartnersSwedbank AB1832 Asset Management L.P. HARRIS ASSOCIATES L PLOOMIS SAYLES & CO L P